3 March 2022
Liver Cancer, Phase 1b Clinical results publication
Major First in Class Clinical data! Genoscience is proud to announce a new cornerstone of…
Read More
You have a question ?
17 January 2022
GNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition
Since December 2019, SARS-CoV-2 has spread quickly worldwide, leading to more than 280 million confirmed…
Read More
17 December 2021
GENOSCIENCE PHARMA out licenses rights of GNS561 in Europe, US and Canada territories in Cholangiocarcinoma
Genoscience is proud to announce the out-licensing of GNS561 in the cholangiocarcinoma in the United…
Read More
8 November 2021
GNS561, a clinical-stage PPT1 inhibitor is efficient against Hepatocarcinoma via modulation of lysosomal functions
The Genoscience Pharma's team and its collaborators are happy of this new publication in Autophagy…
Read More
13 September 2021
GNS561, active against Cancer Stem Cells.
A new article has been recently published in the #journalofcancer showing that #GNS561, a new #autophagy blocker, offers great…
Read More
January 11-16, 2021
Biotech Showcase™ 2021
Biotech Showcase™ 2021_ Investor Digital Conference Excited to attend the 2021 Digital Investor Conference which…
Read More
November 19-20, 2020
2020 Drugging Autophagy Summit
Genoscience Pharma has presented at The Drugging Autophagy Summit its Phase 1b results, where all…
Read More
Nov. 18, 2020
GNS561’s successful phase 1b trial completed
Genoscience Pharma completes successful phase 1b trial evaluating GNS561, PPT-1 inhibitor, in patients with primary…
Read More
July 22, 2020
GNS561, a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-β1 inhibition
Marseille, July 22, 2020_ Therapeutic Advances in Chronic disease just published Genoscience Pharma's article E…
Read More
18 June, 2020
Our COVID-19 research Project supported by the French Government
Marseille, June 18, 2020_ The French Government announced in today's press release that Genoscience Pharma…
Read More
